Literature DB >> 16912956

Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

Marylyn D Ritchie1, David W Haas, Alison A Motsinger, John P Donahue, Huso Erdem, Stephen Raffanti, Peter Rebeiro, Alfred L George, Richard B Kim, Jonathan L Haines, Timothy R Sterling.   

Abstract

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16912956     DOI： 10.1086/507101

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  29 in total

1.  PharmGKB summary: very important pharmacogene information for CYP2B6.

Authors:  Caroline F Thorn; Jatinder K Lamba; Vishal Lamba; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-08       Impact factor: 2.089

Review 2.  Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

Authors:  Antonio Aceti; Laura Gianserra; Lara Lambiase; Alfredo Pennica; Elisabetta Teti
Journal:  World J Virol       Date:  2015-08-12

3.  Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Authors:  Victor Asensi; Julio Collazos; Eulalia Valle-Garay
Journal:  World J Virol       Date:  2015-08-12

Review 4.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Clinical perspectives on human genetic screening to prevent nevirapine toxicity.

Authors:  David W Haas; Piroon Mootsikapun; Kiat Ruxrungtham; Daniel Podzamczer
Journal:  Per Med       Date:  2012-09-01       Impact factor: 2.512

Review 6.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 7.  Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Authors:  Andrea Calcagno; Jessica Cusato; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

8.  Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

Authors:  Todd Hulgan; John P Donahue; Laura Smeaton; Minya Pu; Hongying Wang; Michael M Lederman; Kimberly Smith; Hernan Valdez; Christopher Pilcher; David W Haas
Journal:  Eur J Clin Pharmacol       Date:  2009-11       Impact factor: 2.953

9.  Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

Authors:  Q Xu; X Wu; M Li; H Huang; C Minica; Z Yi; G Wang; L Shen; Q Xing; Y Shi; L He; S Qin
Journal:  Pharmacogenomics J       Date:  2015-08-18       Impact factor: 3.550

10.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Authors:  Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen
Journal:  J Antimicrob Chemother       Date:  2008-02-14       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.